Literature DB >> 30139875

Early-Life Alcohol Intake and High-Grade Prostate Cancer: Results from an Equal-Access, Racially Diverse Biopsy Cohort.

Jamie Michael1, Lauren E Howard2, Sarah C Markt3, Amanda De Hoedt1, Charlotte Bailey1, Lorelei A Mucci3, Stephen J Freedland1,4, Emma H Allott5,6,7.   

Abstract

Epidemiologic evidence for an association between alcohol and prostate cancer is mixed. Moreover, there is a lack of research investigating early-life alcohol intake as a risk factor for either overall or high-grade prostate cancer. We examined lifetime alcohol intake in association with prostate cancer diagnosis in an equal-access, racially diverse prostate biopsy cohort. Men undergoing prostate biopsy at the Durham Veterans Affairs Medical Center from 2007 to 2018 completed a survey indicating average number of alcoholic beverages consumed per week [categorized as none (ref), 1-6, ≥7] during each decade of life. Multivariable logistic regression was used to test the association between alcohol intake across decades and diagnosis of overall, low-grade [grade group (GG) 1-2] and high-grade prostate cancer (GG 3-5). Of 650 men ages 49-89 who underwent biopsy, 325 were diagnosed with prostate cancer, 238 with low-grade and 88 with high-grade disease. Relative to nondrinkers, men who consumed ≥7 drinks/week at ages 15 to 19 had increased odds of high-grade prostate cancer diagnosis (OR = 3.21, P trend = 0.020), with similar findings for ages 20 to 29, 30 to 39, and 40 to 49. Consistent with these results, men in the upper tertile of cumulative lifetime intake had increased odds of high-grade prostate cancer diagnosis (OR = 3.20, P trend = 0.003). In contrast, current alcohol intake was not associated with prostate cancer. In conclusion, among men undergoing prostate biopsy, heavier alcohol intake earlier in life and higher cumulative lifetime intake were positively associated with high-grade prostate cancer diagnosis, while current intake was unrelated to prostate cancer. Our findings suggest that earlier-life alcohol intake should be explored as a potential risk factor for high-grade prostate cancer. Cancer Prev Res; 11(10); 621-8. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2018        PMID: 30139875     DOI: 10.1158/1940-6207.CAPR-18-0057

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  6 in total

Review 1.  The Impact of Lifestyle on Prostate Cancer: A Road to the Discovery of New Biomarkers.

Authors:  Catarina Leitão; Bárbara Matos; Fátima Roque; Maria Teresa Herdeiro; Margarida Fardilha
Journal:  J Clin Med       Date:  2022-05-22       Impact factor: 4.964

Review 2.  Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part I.

Authors:  Mark A Moyad
Journal:  Curr Urol Rep       Date:  2018-10-27       Impact factor: 3.092

Review 3.  Clinical factors affecting prostate-specific antigen levels in prostate cancer patients undergoing radical prostatectomy: a retrospective study.

Authors:  Giovanni Tarantino; Felice Crocetto; Concetta Di Vito; Raffaele Martino; Savio Domenico Pandolfo; Massimiliano Creta; Achille Aveta; Carlo Buonerba; Ciro Imbimbo
Journal:  Future Sci OA       Date:  2021-01-12

4.  Energy Metabolism-Related Gene Prognostic Index Predicts Biochemical Recurrence for Patients With Prostate Cancer Undergoing Radical Prostatectomy.

Authors:  Dechao Feng; Xu Shi; Facai Zhang; Qiao Xiong; Qiang Wei; Lu Yang
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

5.  Mitochondrial Aldehyde Dehydrogenase 2 Represents a Potential Biomarker of Biochemical Recurrence in Prostate Cancer Patients.

Authors:  Dechao Feng; Weizhen Zhu; Jia You; Xu Shi; Ping Han; Wuran Wei; Qiang Wei; Lu Yang
Journal:  Molecules       Date:  2022-09-15       Impact factor: 4.927

Review 6.  Alcohol and Prostate Cancer: Time to Draw Conclusions.

Authors:  Amanda J Macke; Armen Petrosyan
Journal:  Biomolecules       Date:  2022-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.